secwatch.observer — SEC 8-K summary
======================================

Issuer:     NeuroPace Inc (NPCE)
CIK:        0001528287
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001528287-23-000033
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroPace Q2 revenue $16.5M (+62% YoY); raises FY 2023 guidance to $59-61M
--------------------------------------------------------------------------

- Q2 revenue $16.5M, up 62% YoY and 14% QoQ; net loss narrowed to $9.1M from $12.7M YoY.
- Full-year 2023 revenue guidance raised to $59-61M (30-34% growth), from prior $52-54M.
- Cash burn reduced to $4M in Q2 from $9.8M in Q1; cash and investments $63.6M at June 30.
- NAUTILUS trial enrollment on track; full enrollment expected Q1 2024 for generalized epilepsy.
- Gross margin 72.5%; operating expenses flat YoY; DIXI product distribution contributed to revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528287/000152828723000033/0001528287-23-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528287/000152828723000033/npce-20230808.htm
  HTML page:      https://secwatch.observer/filing/0001528287-23-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer